X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through this merger, Sun Pharma will gain access to Taro's pipelines, enabling further commercialization in the market, including Diamox (acetazolamide), an carbonic anhydrase inhibitor used for treating edema due to congestive heart failure in patients.
Lead Product(s): Acetazolamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Diamox
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 17, 2024
Details:
Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory (PDD) of Health Canada.
Lead Product(s): Desvenlafaxine Succinate
Therapeutic Area: Psychiatry/Psychology Product Name: Desvenlafaxine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Intellipharmaceutics Corp.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 16, 2022
Details:
Taro Pharmaceutical Industries, has agreed to acquire all of the outstanding capital stock of Galderma ; Proactiv YK ; The Proactiv Company ; used in the business of developing, manufacturing, marketing, selling and distributing products sold under the Proactiv, Skin brands.
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Proactiv
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Galderma
Deal Size: $99.3 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 09, 2022
Details:
The acquisition includes Alchemee’s business and assets worldwide, including the Proactiv® brand. Alchemee's flagship brand, Proactiv, is America’s 1 acne routine and has been used and trusted by millions around the world for more than 25 years.
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Proactiv
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Alchemee
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 28, 2022
Details:
Deferiprone is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of Ferriprox®.
Lead Product(s): Deferiprone
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.
Lead Product(s): Lidocaine,Tetracaine
Therapeutic Area: Neurology Product Name: Pliaglis
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Crescita Therapeutics
Deal Size: Undisclosed Upfront Cash: $3.9 million
Deal Type: Licensing Agreement July 28, 2020
Details:
NTC Srl has granted exclusive license and distribution rights to one of its R&D products to Taro Pharmaceutical. The product combines a quinolone antibiotic with an anti-inflammatory steroid in eye drops intended to provide an appropriate treatment for post-cataract surgery.
Lead Product(s): Levofloxacin,Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: NTC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
